Article
ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field
Rating:
0.0
Views:
34
Likes:
1
Library:
1
Allogene Therapeutics has linked its off-the-shelf anti-BCMA CAR-T cell therapy to a 60% response rate in a phase 1 trial. The candidate is up against autologous cell therapies that have set the efficacy bar high, but Allogene has off-the-shelf advantages and levers to pull to further improve outcomes.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value